A5039517708- Cancer Immunotherapy and Biomarkers
- Mycobacterium research and diagnosis
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Tuberculosis Research and Epidemiology
- Cancer Research and Treatments
- COVID-19 Clinical Research Studies
- Immune responses and vaccinations
- SARS-CoV-2 and COVID-19 Research
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Diagnosis and Treatment
- Research on Leishmaniasis Studies
- Bladder and Urothelial Cancer Treatments
- Inflammasome and immune disorders
- Genetic factors in colorectal cancer
- Pharmacological Effects of Natural Compounds
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Cell Adhesion Molecules Research
- Medication Adherence and Compliance
- Cancer therapeutics and mechanisms
- Pericarditis and Cardiac Tamponade
- Ferroptosis and cancer prognosis
- Acute Lymphoblastic Leukemia research
Cadila Pharmaceuticals (India)
2012-2024
Pennsylvania State University
2007
Medical College and Hospital, Kolkata
2006
Prolonged treatment of tuberculosis (TB) often leads to poor compliance, default and relapse, converting primary TB patients into category II (Cat IITB) cases, many whom may convert multi-drug resistant (MDR-TB). We have evaluated the immunotherapeutic potential Mycobacterium indicus pranii (MIP) as an adjunct Anti-Tubercular Treatment (ATT) in Cat pulmonary (PTB) a prospective, randomized, double blind, placebo controlled, multicentric clinical trial. 890 sputum smear positive PTB were...
Abstract Introduction: Desmocollin-3 (DSC3), a transmembrane glycoprotein is expressed in various cancers like squamous lung, head & neck, Cervical, Melanoma, bladder cancer etc. DSC3 also predictive biomarker for efficacy of Mycobacterium w (Mw) vaccine, heat-killed suspension non-pathogenic mycobacterium. It induces DSC3-specific cell-mediated (CD8+ T cells) immune response and considered to be barrier infiltrate. Efficacy anti-PD1/PDl1 therapy depends on tumor infiltrating cells....
The kinetics of NKG2C + adaptive natural killer (ANK) cells and NKG2A inhibitory NK (iNK) with respect to the incidence SARS-CoV-2 infection were studied for 6 months in a cohort healthcare workers following administration heat-killed Mycobacterium w (Mw group) comparison control group. In both groups, corona virus disease 2019 (COVID-19) correlated lower ANK at baseline. There was significant upregulation expression IFN-γ release Mw group (p=0.0009), particularly those baseline expression,...
Precise regulation of inflammasome is critical during any pathogenic encounter. The whole innate immune system comprising pattern recognition receptors (PRRs) relies on its ability to sense microbes. fate cellular death in infected cells depends mostly the activation these inflammasome, dysregulation which, due functional manipulation by various pathogens, leads be cause many human diseases. Here, an interesting finding has been observed which related how Leishmania donovani parasites...
Visceral leishmaniasis, one of the fatal forms disease, is caused by Leishmania donovani and presents morbid clinical manifestations. The parasite evades pro-inflammatory immune responses several reported mechanisms modulates host system to cause symptoms. A plethora reports related role BLIMP-1 its involvement in suppressing response various infectious diseases have been documented. Higher parasitic burden due increased production has earlier for malaria leishmaniasis with no detailed...
Mycobacterium-w (Mw) was shown to boost adaptive natural killer (ANK) cells and protect against COVID-19 during the first wave of pandemic. As a follow-up trial, 50 healthcare workers (HCW) who had received Mw in September 2020 subsequently at least one dose ChAdOx1 nCoV-19 vaccine (Mw + group) were monitored for symptomatic major outbreak with delta variant SARS-CoV-2 (April–June 2021), along 201 HCW receiving both doses without (ChAdOx1 group). Despite 48% having just single group, only...
7501 Background: TLR2 agonist, mycobacterium w (Cadi-05), a non-specific immunomodulator and pure Th 1 response enhancer has demonstrated synergistic effects with number of chemotherapeutic agents. A phase II randomized study was conducted to test the efficacy combination paclitaxel plus cisplatin or without Cadi-05 as first line treatment advanced NSCLC. Methods: Two hundred twenty-one naïve patients (pts) stage IIIB IV NSCLC were receive 175mg/m2 3-hour infusion 100mg/m2 administered...
Abstract Introduction: Desmocollin-3 (DSC3) is used for differentiating squamous lung cancer from non-squamous. Its expression known to be altered in various cancers. Based on DSC3 gene cancers can divided into two broad groups. Those with higher level e.g. Squamous (SCL), Head and Neck (HNC), Cervical (CEC) those lower Adenocarcinoma of (ACL), bladder (BC), Renal (REC), Uterine endometrial (UEC) Stomach adenocarcinoma (STAC) . There some evidence being prognostic biomarker NSCLC (SCL). also...
Abstract Introduction: Desmocollin-3 (DSC3) is a transmembrane glycoprotein. It p53-responsive desmosomal cadherin protein and takes part in signaling. used to differentiate squamous lung cancer from non-squamous cancer. Its expression known be altered various cancers. Like other adhesion molecules, it also act as barrier tumor infiltration by immune cells (TIL). Previous studies have shown that the Mycobacterium w (Mw) vaccine, heat-killed suspension of non-pathogenic mycobacterium, induces...
Abstract Osteosarcoma (OS) is the most common malignant primary tumor of bone and occurs in adolescents young adults as well elderly. Despite a number large clinical trial efforts, metastatic sarcoma remains lethal disease, there have been no meaningful advances therapy or improvements patient outcomes for decades. Mycobacterium w (Mw, also known indicus pranii) non-pathogenic strain mycobacterium which has used an immunomodulator against leprosy, tuberculosis several cancers approved...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with overall 5-year survival rate of <10% due to late stage diagnosis and poor clinical outcome existing therapies. PDAC displays a high degree tumor heterogeneity immunosuppressive microenvironment lower infiltrating lymphocytes (TIL). These factors contribute resistance against chemotherapies immunotherapies. Immunotherapies have shown activities across different types including chemotherapy or targeted...
Immunotherapy is a fourth pillar in cancer management after surgery, radiotherapy and chemotherapy. Active immunotherapy works by inducing antigen specific immune response following its administration while checkpoint inhibitor reducing tumor induced immunosuppression thereby utilizing pre-existing response. Adoptive cell therapy (ACT) type of personalized wherein cells are harvested from patient, expanded reintroduced. The T genetically modified chimeric receptor (CAR-T) infiltrating used...
Abstract To evaluate ability of modulated innate immune response to provide resistance development symptomatic RT-PCR confirmed COVID-19, 96 inpatient front line health care workers (HCW) were cohorted in 1:2 ratio receive TLR2 agonist (heat killed Mycobacterium w, Mw; n=32) as modulator or observation (n=64). All followed up for 100 days. The incidence COVID-19 was 31 (32.3%) the entire cohort, with only one developing Mw group (3.1% vs 46.8%. protective efficacy - 93.33%, p=0.0001; 95% CI...
Desmocollin-3 (DSC3) is DSC3 protein coding gene, expressed in some epithelial cancers.DSC3 expression has prognostic value cancers.Using cBioportal and Kaplan-Meier plotter gene was evaluated 12 cancers using TCGA data compared with Hallmark expression.Cancers were grouped to have low (Group I), intermediate II) high III) expression.Higher group III associated better survival I poor survival.DSC3 correlated desmosomal genes DSG3, DSC1, DSG1, PKP1 spite of its known reciprocal relationship...